ABCL (STOCKS)
AbCellera Biologics Inc. Common Shares
$3.789300
+0.129300 (+3.53%)
Prev close: $3.660000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Carl Lars G. Hansen
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $1,139.88M
- Employees
- 596
- P/E (TTM)
- -7.67
- P/B (TTM)
- 1.17
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
9
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.03 | $-0.18 | +0.1475 | +83.10% |
|
Sep 2025 (Q3)
|
$-0.19 | $-0.17 | -0.0179 | -10.40% |
|
Jun 2025 (Q2)
|
$-0.12 | $-0.17 | +0.0493 | +29.12% |
|
Mar 2025 (Q1)
|
$-0.15 | $-0.14 | -0.0052 | -3.59% |
Financial Statements
| Revenues | $75.13M |
| Benefits Costs and Expenses | $252.72M |
| Costs And Expenses | $252.72M |
| Nonoperating Income/Loss | $39.51M |
| Operating Expenses | $292.23M |
| Research and Development | $186.83M |
| Other Operating Expenses | $105.40M |
| Operating Income/Loss | -$217.10M |
| Income/Loss From Continuing Operations After Tax | -$146.41M |
| Income/Loss From Continuing Operations Before Tax | -$177.60M |
| Income Tax Expense/Benefit | -$31.18M |
| Income Tax Expense/Benefit, Current | -$30.25M |
| Net Income/Loss | -$146.41M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$146.41M |
| Net Income/Loss Available To Common Stockholders, Basic | -$146.41M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.49 |
| Diluted Earnings Per Share | -$0.49 |
| Basic Average Shares | 298,707,082 |
| Diluted Average Shares | 298,707,082 |
| Assets | $1.36B |
| Current Assets | $728.23M |
| Cash | $533.83M |
| Accounts Receivable | $39.41M |
| Inventory | $6.34M |
| Other Current Assets | $148.66M |
| Noncurrent Assets | $628.72M |
| Intangible Assets | $38.38M |
| Other Non-current Assets | $590.34M |
| Liabilities | $390.05M |
| Current Liabilities | $64.31M |
| Wages | $10.76M |
| Other Current Liabilities | $53.55M |
| Noncurrent Liabilities | $325.74M |
| Equity | $966.90M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $966.90M |
| Liabilities And Equity | $1.36B |
| Net Cash Flow From Operating Activities | -$131.30M |
| Net Cash Flow From Operating Activities, Continuing | -$131.30M |
| Net Cash Flow From Investing Activities | $87.75M |
| Net Cash Flow From Investing Activities, Continuing | $87.75M |
| Net Cash Flow From Financing Activities | $14.08M |
| Net Cash Flow From Financing Activities, Continuing | $14.08M |
| Exchange Gains/Losses | $1.10M |
| Net Cash Flow | -$28.37M |
| Net Cash Flow, Continuing | -$29.46M |
| Comprehensive Income/Loss | -$146.27M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$146.27M |
| Other Comprehensive Income/Loss | $144.00K |